Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction (Q46699523)

24 December 2017

title

Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction (English)

1 reference

24 December 2017

Gerd Hasenfuss

1 reference

24 December 2017

Claudius Jacobshagen

1 reference

24 December 2017

Meike Grüber

1 reference

24 December 2017

Nils Teucher

1 reference

24 December 2017

Albrecht G Schmidt

1 reference

24 December 2017

Bernhard W Unsöld

1 reference

24 December 2017

Karl Toischer

1 reference

24 December 2017

Van Phuc Nguyen

1 reference

24 December 2017

Lars S Maier

1 reference

24 December 2017

Harald Kögler

1 reference

24 December 2017

publication date

17 March 2008

1 reference

24 December 2017

European Journal of Heart Failure

published in

1 reference

24 December 2017

volume

1 reference

24 December 2017

issue

1 reference

24 December 2017

page(s)

334-342

1 reference

24 December 2017

Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Regulation of cardiac hypertrophy by intracellular signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Hypertrophy of the heart: a new therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Synchronization and integration of multiple hypertrophic pathways in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Prognostic implications of left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Akt1 in the cardiovascular system: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Ultrarapid, highly efficient viral gene transfer to the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

21 January 2018

The renaissance of GSK3

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Signaling pathways for cardiac hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Akt/protein kinase B promotes organ growth in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

The conserved phosphoinositide 3-kinase pathway determines heart size in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Rapamycin attenuates load-induced cardiac hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.02.013

10.1016/J.EJHEART.2008.02.013

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017